Compositions for Correcting Age Related Changes of a Human Endocrine System and Methods for Producing a Pharmaceutical Form Bases on Said Compositions

• US 20090011041A1
• Filed: 04/04/2005
• Published: 01/08/2009
• Est. Priority Date: 04/26/2004
• Status: Abandoned Application

• Current Assignee: Obschestvo S Ogranichennoi Otvetstvennostyu 'Rusgen'
• Original Assignee: Obschestvo S Ogranichennoi Otvetstvennostyu 'Rusgen'
• Inventors: Perminova, Irina Olegovna, Smirnova, Olga Vyacheslavovna, Musaeva, Adilya Rafik kyzy, Kuzina, Irina Nikolaevna, Bogorad, Roman Lvovich
• Application Number:
  US11/587,351
• Publication Number:
  US 20090011041A1
• Time in Patent Office: Days
• US Class Current: 424/520
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 36/258 Panax (ginseng)
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system

Abstract

The present invention relates to anti-aging pharmacology and is intended for correction of age-related changes in human endocrine system. The essence of the invention is the compositions for correction of certain age-related endocrine changes and method for production of pharmaceutical form based thereon. Each composition contains a mixture of substances exhibiting hormonal activity (HA) or hormone-like activity (HLA) selected from the group: C21 or C19 steroids, pregnenolone, 17-hydroxypregnenolone, DHEA, progesterone, testosterone, or a hormone-like substance of herbal origin (HS), and also a dry methanolic of Nettle root extract, taken in a definite ratio, wherein HA, HLA or HS with the Nettle root extract can further contain a Deer Antler velvet extract and/or Ginseng root extract, and HS can comprise diosgenin or protodioscin. One variant of the composition is a mixture of a dry Ginseng root extract and a dry Nettle root extract. The inventive method for production of said pharmaceutical form consists in mixing an active component and pharmaceutically acceptable carrier with suitable adjuvants in an effective amount. The useful result is in broadening the range of natural agents able to correct age-related hormonal changes in human organism.

Claims

1. A composition a substance with hormonal activity (HA) or with hormone-like activity (HLA) selected from the group:

C21 or C19 steroids, pregnenolone, 17-hydroxypregnenolone, DHEA, progesterone, testosterone, or a hormone-like substance of herbal origin (HS) or a mixture of two or more thereof, and also a dry methanolic extract of Nettle root with the following ratio of the components (weight parts);

HA, HLA or HS 0.0001-25.0 a Nettle root extract  

0.05-50.0.

2. The composition of claim 1, which contains HS in the form of phytochemical compounds such as diosgenin or protodioscin.

3. The composition of claim 1, which further contains a dry Deer Antler velvet extract in an amount of 0.00001-100.

4. The composition of claim 2, which further contains a dry Deer Antler velvet extract in an amount of 0.00001-10.0

5. The composition of claim 2, which further contains a dry Ginseng root extract in an amount of 0.00001-60.0.

6. The composition of claim 3, which further contains a dry ginseng root extract in an amount of 0.00001-60.0.

7. A composition, comprising a hormone-like substance of herbal origin a dry Ginseng root extract and a dry Nettle root extract with the following ratio of the components (weight parts):

Ginseng extract 0.0001-60.0 Nettle root extract  

0.005-50.0.

8. A method for production of a pharmaceutical form which includes mixing of an active component and pharmaceutically acceptable carrier with suitable adjuvants wherein said active component comprises an effective amount of a composition including a substance with hormonal activity (HA) or with hormone-like activity (HLA) selected from the group:

C21 or C19 steroids, pregnenolone 17-hydroxypregnenolone DHEA progesterone testosterone or a hormone-like substance of herbal origin (HS) or a mixture of two or more thereof and also a dry methanolic extract of Nettle root with the following ratio of the components (weight parts);

HA, HLA or HS 0.0001-25.0 a Nettle root extract  

0.05-50.0.

9. The method for producing a pharmaceutical form of claim 8, comprising the introduction of an active component into the formulation in a concentration of no less than 1.5%.

10. The method of claim 8, wherein solid, soft or liquid substances are used as the carrier.

11. The method of claim 8, wherein the form is produced with the use of solid carriers, wherein the end form is a tablet, a dragee, a granule, a sachet, or a powder placed into a capsule.

12. The method of claim 8, wherein the form is produced with the use of liquid carriers, wherein the end product is a solution, a gel, an emulsion, a suspension, a potion, a syrup or a liniment.

13. The method of claim 8, wherein the form is produced with the use of soft carriers, wherein the end product is an ointment, a crè

me, a paste, a suppository, an implant, or a chewing tablet or a troche.

14. The method of claim 8, wherein the produced form is used in a suitable manner, selected from the group consisting of oral administration, sublingual administration, intranasal administration, rectal administration, vaginal administration, parenteral administration, subconjunctival administration, or a chewable form.

15. A method for production of a pharmaceutical form which includes mixing an active component and pharmaceutically acceptable carrier with suitable adjuvants wherein said active component comprises an effective amount of a composition including a hormone-like substance of herbal origin, a dry Ginseng root extract and a dry Nettle root extract with the following ratio of the components (weight parts):

Ginseng extract 0.0001-60.0 Nettle root extract  

0.005-50.0.

16. The method for producing a pharmaceutical form of claim 15, comprising the introduction of an active component into the formulation in a concentration of no less than 1.5%.

17. The method of claim 15, wherein solid, soft or liquid substances are used as the carrier.

18. The method of claim 15, wherein the form is produced with the use of solid carriers, wherein the end form is a tablet, a dragee, a granule, a sachet, or a powder placed into a capsule.

19. The method of claim 15, wherein the form is produced with the use of liquid carriers, wherein the end product is a solution, a gel, an emulsion, a suspension, a potion, a syrup or a liniment.

20. The method of claim 15, wherein the form is produced with the use of soft carriers, wherein the end product is an ointment, a crè

me, a paste, a suppository, an implant, or a chewing tablet or a troche.

21. The method of claim 15, wherein the produced form is used in a suitable manner, selected from the group consisting of oral administration, sublingual administration, intranasal administration, rectal administration, vaginal administration, parenteral administration, subconjunctival administration, or a chewable form.